{"product_id":"myopia-control-in-children-a-complete-patients-guide-to-the-2023-cochrane-review","title":"Myopia Control in Children: A Complete Patient's Guide to the 2023 Cochrane Review","description":"\u003cp\u003eMyopia (nearsightedness) is a growing worldwide problem, and children are most affected because their eyes change the fastest. This living systematic review and network meta-analysis, published by the Cochrane Collaboration in 2023, combined data from 64 randomized controlled trials involving 11,617 children ages 4 to 18 to compare medications, specialized glasses, and contact lenses designed to slow myopia progression. The review found that atropine eye drops—particularly at higher doses—were the most effective at slowing both the worsening of blurry distance vision and the abnormal elongation of the eyeball that causes myopia. Several optical options, including multifocal soft contact lenses and special progressive-addition glasses, also showed meaningful benefits at one and two years, while undercorrected single-vision spectacles and rigid gas-permeable lenses showed little to no benefit.\u003c\/p\u003e\n\n\u003ch1\u003eMyopia Control in Children: A Complete Patient's Guide to the 2023 Cochrane Review\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#understanding-myopia\"\u003eUnderstanding Myopia (Nearsightedness)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-this-matters\"\u003eWhy Slowing Myopia in Childhood Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-methods\"\u003eHow the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings-sight\"\u003eKey Findings: Changes in Blurred Vision (Refractive Error)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings-length\"\u003eKey Findings: Eyeball Length (Axial Elongation)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rebound\"\u003eWhat Happens When Treatment Stops? (The 'Rebound' Question)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSafety and Side Effects\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients and Families\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Parents and Caregivers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAtropine eye drops, especially high-dose, were the most effective at slowing myopia and eyeball growth in children.\u003c\/li\u003e\n\u003cli\u003eMultifocal soft contact lenses and multifocal spectacles showed consistent, modest benefits at one and two years.\u003c\/li\u003e\n\u003cli\u003eUndercorrected single-vision glasses and rigid gas-permeable lenses showed little or no benefit for myopia control.\u003c\/li\u003e\n\u003cli\u003eThe rebound effect after stopping treatment is uncertain; evidence at two years is limited and adverse events were poorly reported.\u003c\/li\u003e\n\u003cli\u003eNo randomized trials of environmental interventions like outdoor time were found for children who already had myopia.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"understanding-myopia\"\u003eUnderstanding Myopia (Nearsightedness)\u003c\/h2\u003e\n\n\u003cp\u003eMyopia—commonly called short-sightedness or nearsightedness—is a condition where the eyeball grows too long. Because of this elongation, light entering the eye focuses in front of the retina instead of directly on it, making distant objects appear blurred while nearby objects remain clear.\u003c\/p\u003e\n\n\u003cp\u003eThis is not a rare problem. The review notes that myopia affects more than half of all children in China and South-East Asia, and its prevalence is rising worldwide. For many children, myopia is first detected before age 10, which matters because younger onset typically means faster progression and a higher final level of nearsightedness.\u003c\/p\u003e\n\n\u003cp\u003eClinicians measure myopia in two important ways:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSpherical equivalent refraction (SER)\u003c\/strong\u003e, measured in diopters (D), which describes how much corrective power the eye needs to see clearly. A higher negative number (for example, going from −2.00 D to −4.00 D) means the myopia is progressing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAxial length\u003c\/strong\u003e, measured in millimeters (mm), which is the physical length of the eyeball from front to back. Longer eyes mean the retina is stretched, increasing future risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"why-this-matters\"\u003eWhy Slowing Myopia in Childhood Matters\u003c\/h2\u003e\n\n\u003cp\u003eSlowing myopia progression is not just about avoiding thick glasses. Because myopic eyes are longer, the retina (the light-sensitive tissue at the back of the eye) becomes stretched and thinned. This puts children at greater risk—when they become adults—of serious eye diseases including \u003cstrong\u003eglaucoma\u003c\/strong\u003e (optic nerve damage), \u003cstrong\u003emaculopathy\u003c\/strong\u003e (damage to the central retina), and \u003cstrong\u003eretinal detachment\u003c\/strong\u003e (where the retina peels away from the eye wall).\u003c\/p\u003e\n\n\u003cp\u003eMyopia can also affect daily life during childhood itself, including educational and occupational activities. The review's authors emphasize that because myopia is usually detected before age 10 and can progress rapidly, any effective intervention needs to be delivered during childhood to have the greatest impact.\u003c\/p\u003e\n\n\u003cp\u003eConventional eyeglasses and standard contact lenses correct the blur but do nothing to slow the underlying progression. That is where \"myopia control\" interventions come in.\u003c\/p\u003e\n\n\u003ch2 id=\"study-methods\"\u003eHow the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis is a \u003cstrong\u003eliving systematic review and network meta-analysis\u003c\/strong\u003e, which means the researchers continuously update their findings as new evidence becomes available. It follows the rigorous methodology of the Cochrane Collaboration, an international organization widely considered a gold standard for evidence-based medicine.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers searched CENTRAL (containing the Cochrane Eyes and Vision Trials Register), MEDLINE, Embase, and three trials registries. The search date was \u003cstrong\u003eFebruary 26, 2022\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat studies were included?\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e64 randomized controlled trials\u003c\/strong\u003e (RCTs)—the most reliable type of medical evidence\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e11,617 children\u003c\/strong\u003e aged 4 to 18 years\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e39 studies (60.9%)\u003c\/strong\u003e conducted in China or other Asian countries\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e13 studies (20.3%)\u003c\/strong\u003e conducted in North America\u003c\/li\u003e\n  \u003cli\u003eStudy durations ranged from \u003cstrong\u003e12 to 36 months\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e57 studies (89%)\u003c\/strong\u003e compared a myopia control intervention against an inactive control (such as placebo drops or standard single-vision glasses)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAll studies were randomized controlled trials of children aged 18 years or younger. The researchers focused on outcomes measured at one year or longer: the difference in change in SER (in diopters) and axial length (in millimeters) between the intervention and control groups. They also examined what happens after treatment stops, sometimes called the \"rebound\" effect.\u003c\/p\u003e\n\n\u003ch3\u003eWhat interventions were studied?\u003c\/h3\u003e\n\n\u003cp\u003eThe review covered three broad categories of treatment:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOptical treatments (glasses and contact lenses):\u003c\/strong\u003e multifocal spectacle lenses, peripheral plus spectacle lenses (PPSL), undercorrected single vision spectacles, multifocal soft contact lenses (MFSCL), orthokeratology (special lenses worn overnight that temporarily reshape the eye's surface), and rigid gas-permeable contact lenses (RGP)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePharmacological treatments (eye drops):\u003c\/strong\u003e high-dose atropine (HDA), moderate-dose atropine (MDA), low-dose atropine (LDA), pirenzepine, and 7-methylxanthine\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEnvironmental interventions:\u003c\/strong\u003e time outdoors, reduced screen time, or other behavioral approaches. Notably, \u003cstrong\u003eno studies\u003c\/strong\u003e reporting environmental interventions for children with existing myopia met the inclusion criteria.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors assessed the risk of bias using the Cochrane Rob 2 tool and rated the certainty of the evidence using the GRADE approach. According to the review, the overall certainty of the evidence ranged from \u003cstrong\u003every low to moderate\u003c\/strong\u003e. Because the networks connecting different treatments were poorly connected, the authors mostly report results from direct pairwise comparisons—meaning head-to-head comparisons between one treatment and a control group.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings-sight\"\u003eKey Findings: Changes in Blurred Vision (Refractive Error)\u003c\/h2\u003e\n\n\u003cp\u003eTo understand these results, it helps to know that a larger \u003cem\u003epositive\u003c\/em\u003e difference means the treatment slowed myopia better than the control. For example, a mean difference (MD) of 0.90 D means the treated children's myopia worsened by 0.90 diopters less than the control group's over one year.\u003c\/p\u003e\n\n\u003ch3\u003eResults at One Year\u003c\/h3\u003e\n\n\u003cp\u003eAt one year, in \u003cstrong\u003e38 studies with 6,525 children analyzed\u003c\/strong\u003e, the median change in SER for children in the control groups was \u003cstrong\u003e−0.65 D\u003c\/strong\u003e—meaning their myopia worsened by about two-thirds of a diopter during the year.\u003c\/p\u003e\n\n\u003cp\u003eCompared with controls, the following interventions slowed the worsening of myopia:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh-dose atropine:\u003c\/strong\u003e MD 0.90 D (95% CI 0.62 to 1.18)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModerate-dose atropine:\u003c\/strong\u003e MD 0.65 D (95% CI 0.27 to 1.03)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeripheral plus spectacle lenses:\u003c\/strong\u003e MD 0.51 D (95% CI 0.19 to 0.82)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow-dose atropine:\u003c\/strong\u003e MD 0.38 D (95% CI 0.10 to 0.66)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePirenzepine:\u003c\/strong\u003e MD 0.32 D (95% CI 0.15 to 0.49)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocal soft contact lenses:\u003c\/strong\u003e MD 0.26 D (95% CI 0.17 to 0.35)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocal spectacles:\u003c\/strong\u003e MD 0.14 D (95% CI 0.08 to 0.21)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBy contrast, there was \u003cstrong\u003elittle or no evidence\u003c\/strong\u003e that the following slowed myopia progression at one year:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRigid gas-permeable contact lenses:\u003c\/strong\u003e MD 0.02 D (95% CI −0.05 to 0.10)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e7-methylxanthine:\u003c\/strong\u003e MD 0.07 D (95% CI −0.09 to 0.24)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUndercorrected single vision spectacles:\u003c\/strong\u003e MD −0.15 D (95% CI −0.29 to 0.00)—in fact, these may have allowed slightly more progression than full correction\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eResults at Two Years\u003c\/h3\u003e\n\n\u003cp\u003eAt two years, in \u003cstrong\u003e26 studies with 4,949 children analyzed\u003c\/strong\u003e, the median change in SER for controls was \u003cstrong\u003e−1.02 D\u003c\/strong\u003e—meaning untreated children typically worsened by roughly one full diopter over two years.\u003c\/p\u003e\n\n\u003cp\u003eThe following treatments still showed a benefit at two years:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh-dose atropine:\u003c\/strong\u003e MD 1.26 D (95% CI 1.17 to 1.36)—the strongest effect of all treatments at any timepoint\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModerate-dose atropine:\u003c\/strong\u003e MD 0.45 D (95% CI 0.08 to 0.83)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePirenzepine:\u003c\/strong\u003e MD 0.41 D (95% CI 0.13 to 0.69)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocal soft contact lenses:\u003c\/strong\u003e MD 0.30 D (95% CI 0.19 to 0.41)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow-dose atropine:\u003c\/strong\u003e MD 0.24 D (95% CI 0.17 to 0.31)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocal spectacles:\u003c\/strong\u003e MD 0.19 D (95% CI 0.08 to 0.30)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeripheral plus spectacle lenses:\u003c\/strong\u003e MD 0.34 D (95% CI −0.08 to 0.76)—may help, but results were inconsistent across studies\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor rigid gas-permeable lenses, one study found a benefit while another found no difference compared with control. Undercorrected single vision spectacles showed no meaningful benefit at two years (MD 0.02 D, 95% CI −0.05 to 0.09).\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings-length\"\u003eKey Findings: Eyeball Length (Axial Elongation)\u003c\/h2\u003e\n\n\u003cp\u003eAxial length is arguably the most important measure for long-term eye health, because stretching of the eyeball is what drives the future risk of glaucoma, maculopathy, and retinal detachment. Here, a \u003cem\u003enegative\u003c\/em\u003e difference is good: it means the treated eye grew less than the control eye. The median axial length increase in control children was \u003cstrong\u003e0.31 mm at one year\u003c\/strong\u003e and \u003cstrong\u003e0.56 mm at two years\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eAxial Length Results at One Year\u003c\/h3\u003e\n\n\u003cp\u003eIn \u003cstrong\u003e36 studies with 6,263 children analyzed\u003c\/strong\u003e, the following treatments reduced eyeball elongation compared with controls:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh-dose atropine:\u003c\/strong\u003e MD −0.33 mm (95% CI −0.35 to −0.30)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModerate-dose atropine:\u003c\/strong\u003e MD −0.28 mm (95% CI −0.38 to −0.17)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOrthokeratology:\u003c\/strong\u003e MD −0.19 mm (95% CI −0.23 to −0.15)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow-dose atropine:\u003c\/strong\u003e MD −0.13 mm (95% CI −0.21 to −0.05)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeripheral plus spectacle lenses:\u003c\/strong\u003e MD −0.13 mm (95% CI −0.24 to −0.03)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocal soft contact lenses:\u003c\/strong\u003e MD −0.11 mm (95% CI −0.13 to −0.09)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePirenzepine:\u003c\/strong\u003e MD −0.10 mm (95% CI −0.18 to −0.02)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocal spectacles:\u003c\/strong\u003e MD −0.06 mm (95% CI −0.09 to −0.04)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThere was little or no evidence that these reduced axial length at one year:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRigid gas-permeable contact lenses:\u003c\/strong\u003e MD 0.02 mm (95% CI −0.05 to 0.10)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e7-methylxanthine:\u003c\/strong\u003e MD 0.03 mm (95% CI −0.10 to 0.03)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUndercorrected single vision spectacles:\u003c\/strong\u003e MD 0.05 mm (95% CI −0.01 to 0.11)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eAxial Length Results at Two Years\u003c\/h3\u003e\n\n\u003cp\u003eIn \u003cstrong\u003e21 studies with 4,169 children analyzed\u003c\/strong\u003e, the following treatments reduced eyeball elongation at two years:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh-dose atropine:\u003c\/strong\u003e MD −0.47 mm (95% CI −0.61 to −0.34)—the strongest effect on axial length\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModerate-dose atropine:\u003c\/strong\u003e MD −0.33 mm (95% CI −0.46 to −0.20)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOrthokeratology:\u003c\/strong\u003e MD −0.28 mm (95% CI −0.38 to −0.19)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow-dose atropine:\u003c\/strong\u003e MD −0.16 mm (95% CI −0.20 to −0.12)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocal soft contact lenses:\u003c\/strong\u003e MD −0.15 mm (95% CI −0.19 to −0.12)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocal spectacles:\u003c\/strong\u003e MD −0.07 mm (95% CI −0.12 to −0.03)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeripheral plus spectacle lenses:\u003c\/strong\u003e MD −0.20 mm (95% CI −0.45 to 0.05)—may help, but results were inconsistent\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eUndercorrected single vision spectacles (MD −0.01 mm, 95% CI −0.06 to 0.03) and rigid gas-permeable contact lenses (MD 0.03 mm, 95% CI −0.05 to 0.12) showed little or no benefit for controlling eyeball growth.\u003c\/p\u003e\n\n\u003ch2 id=\"rebound\"\u003eWhat Happens When Treatment Stops? (The 'Rebound' Question)\u003c\/h2\u003e\n\n\u003cp\u003eA major concern with any myopia control treatment is whether the eye \"rebounds\"—that is, whether myopia progresses faster than normal after the treatment is discontinued. The review looked specifically at changes in SER and axial length during the year after stopping treatment.\u003c\/p\u003e\n\n\u003cp\u003eThe authors report there was \u003cstrong\u003einconclusive evidence\u003c\/strong\u003e on whether treatment cessation increases myopia progression. In other words, we still do not know for certain whether the benefits last after treatment ends, whether there is an acceleration of myopia, or how best to taper treatments to prevent rebound. This is an important area for future research.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSafety and Side Effects\u003c\/h2\u003e\n\n\u003cp\u003eThe review found that \u003cstrong\u003eadverse events and treatment adherence were not consistently reported\u003c\/strong\u003e across the included studies, creating significant uncertainty about the safety profile of these treatments. Only \u003cstrong\u003eone study\u003c\/strong\u003e reported quality of life outcomes, which is a major gap in the evidence.\u003c\/p\u003e\n\n\u003cp\u003eBased on what is known from the trials and the plain language summary, the key side effects to be aware of include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAtropine eye drops:\u003c\/strong\u003e can cause increased sensitivity to glare and difficulty reading (because the drops dilate the pupil and affect the eye's ability to focus up close). These problems are more common and more severe at higher doses.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSoft contact lenses and orthokeratology:\u003c\/strong\u003e any contact lens wear increases the risk of infections on the surface of the eye (the cornea). Orthokeratology lenses are worn overnight, which adds additional considerations for hygiene and eye health.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe review authors specifically call for \"improved methods for monitoring and reporting adverse effects\" in future studies.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients and Families\u003c\/h2\u003e\n\n\u003cp\u003eThis review provides the most comprehensive picture to date of which myopia control strategies actually work in children. The practical takeaways are clear:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAtropine eye drops work, and higher doses work better.\u003c\/strong\u003e High-dose atropine slowed myopia progression by about 0.90 D at one year and more than 1.25 D at two years, and was the most powerful treatment for reducing eyeball elongation. The trade-off is more side effects at higher doses, such as glare and difficulty with near vision.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeveral optical options are genuinely effective, though modestly.\u003c\/strong\u003e Multifocal soft contact lenses and multifocal spectacles produced consistent, measurable benefits at one and two years for both blur progression and eyeball length. Peripheral plus spectacle lenses also appear promising, though results were less consistent.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOrthokeratology is effective at slowing eyeball growth.\u003c\/strong\u003e Even though the review could not measure SER changes for orthokeratology (because the lenses reshape the cornea in a way that confounds standard refraction measurements), they clearly reduced axial elongation (−0.19 mm at one year and −0.28 mm at two years). Since axial length is what drives long-term eye disease risk, this is clinically meaningful.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSome older treatments appear ineffective.\u003c\/strong\u003e Undercorrecting a child's glasses—deliberately prescribing a weaker prescription—does not slow myopia and may even allow slightly more progression. Rigid gas-permeable contact lenses (as traditionally fitted) also showed no benefit for myopia control.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe durability of benefit is uncertain.\u003c\/strong\u003e The evidence is strongest for one year of treatment, with a smaller body of evidence at two or three years. Longer-term data are especially important because children typically remain myopic for many more years after treatment begins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eImportantly, the review did \u003cstrong\u003enot\u003c\/strong\u003e find any randomized trials of environmental interventions (like increasing outdoor time) in children who already had myopia, and found \u003cstrong\u003eno economic evaluations\u003c\/strong\u003e of myopia control interventions. This means we cannot yet draw conclusions about the cost-effectiveness of these treatments or whether lifestyle measures can slow progression once myopia has already developed.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to understand what this review could not tell us:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModest certainty of evidence.\u003c\/strong\u003e The overall certainty of the evidence ranged from very low to moderate, meaning future research may change these conclusions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoorly connected network.\u003c\/strong\u003e Because the studies did not compare treatments directly against one another in a well-connected network, the researchers could not rely on the network meta-analysis results and had to use simpler direct comparisons. This limits their ability to rank all treatments against each other with precision.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResults were often heterogeneous (inconsistent).\u003c\/strong\u003e Children in different studies had different ages, ethnicities, baselines amounts of myopia, and treatment durations, and results sometimes varied even for the same treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoor reporting of harms and adherence.\u003c\/strong\u003e Most studies did not consistently report side effects or how well children stuck with their treatment, so the true safety picture is incomplete.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSparse long-term data.\u003c\/strong\u003e Most evidence is at one year; far fewer studies extended to two or three years. The question of whether benefits persist after treatment stops remains unresolved.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo data on quality of life.\u003c\/strong\u003e Only one study measured how treatment affected children's daily lives, comfort, or satisfaction.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEconomic information is missing.\u003c\/strong\u003e No economic evaluations met the inclusion criteria, so we cannot compare the cost-effectiveness of these treatments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese limitations do not invalidate the findings, but they explain why the review authors urge caution and call for better, longer-term research.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Parents and Caregivers\u003c\/h2\u003e\n\n\u003cp\u003eIf your child has been diagnosed with myopia, here are practical steps based on this review's findings:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTalk to an eye care professional about myopia control options early.\u003c\/strong\u003e Because myopia progresses fastest in childhood, early intervention matters. Ask specifically about atropine eye drops, multifocal soft contact lenses, multifocal spectacles, peripheral plus lenses, and orthokeratology.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about the dose if atropine is recommended.\u003c\/strong\u003e Higher doses are more effective but cause more glare and difficulty reading. Low-dose atropine is less effective but may have fewer side effects. The decision should be individualized for your child.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider combining treatments.\u003c\/strong\u003e The review notes there is limited evidence on combinations (for example, orthokeratology plus atropine), but combined approaches are increasingly used in practice and are an important area of study.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInsist on proper hygiene for contact lenses.\u003c\/strong\u003e Both soft multifocal lenses and orthokeratology increase the risk of eye infections. Follow cleaning, replacement, and wearing schedules exactly, and report any redness, pain, or blurred vision promptly.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo NOT accept undercorrected glasses as a myopia control strategy.\u003c\/strong\u003e The evidence shows this approach does not work. Children should wear their full, accurate prescription.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect to be part of ongoing monitoring.\u003c\/strong\u003e Myopia control is not a one-time fix. Long-term follow-up is necessary to assess whether treatment is working and to watch for rebound when treatment is eventually discontinued.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about lifestyle measures, but understand the current evidence gap.\u003c\/strong\u003e Outdoor time is widely recommended to help prevent myopia from developing, but this review found no randomized trials testing environmental interventions in children who already have myopia. It is still reasonable to encourage outdoor activity for general health, but do not rely on it as sole treatment.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eFinally, keep in mind that every child is different. What works well for one child may not be ideal for another due to age, the severity of myopia, lifestyle, comfort with contact lenses, and tolerance of side effects. A shared decision between you, your child, and their eye care professional is the best approach.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is myopia and why is it important to slow it down in children?\u003c\/h3\u003e\n\u003cp\u003eMyopia, or nearsightedness, happens when the eyeball grows too long so distant objects look blurry. Slowing it in childhood matters because myopic eyes are longer, stretching the retina. This raises a child’s future risk of serious eye diseases such as glaucoma, maculopathy, and retinal detachment.\u003c\/p\u003e\n\u003ch3\u003eWhat was the most effective treatment for slowing myopia in children?\u003c\/h3\u003e\n\u003cp\u003eHigh-dose atropine eye drops were the most effective at slowing both blurred vision and eyeball elongation. At one year, they slowed myopia progression by about 0.90 diopters more than controls, and at two years, by about 1.26 diopters. However, higher doses cause more side effects like glare and difficulty reading.\u003c\/p\u003e\n\u003ch3\u003eDo eyeglasses help control myopia progression in children?\u003c\/h3\u003e\n\u003cp\u003eSome do. Multifocal spectacles and peripheral plus lenses slowed myopia at one year, with effects continuing at two years. But deliberately undercorrecting a child’s glasses—giving a weaker prescription—did not slow progression and may even allow slightly more worsening. Children should wear their full, accurate prescription.\u003c\/p\u003e\n\u003ch3\u003eWhat are the side effects of atropine eye drops for myopia control?\u003c\/h3\u003e\n\u003cp\u003eAtropine eye drops can cause increased sensitivity to glare and difficulty reading because they dilate the pupil and affect near focusing. These problems are more common and more severe at higher doses. Lower doses may have fewer side effects but are less effective in slowing myopia.\u003c\/p\u003e\n\u003ch3\u003eIf my child stops myopia control treatment, will the myopia get worse?\u003c\/h3\u003e\n\u003cp\u003eThe review found inconclusive evidence on whether stopping treatment causes a 'rebound' acceleration of myopia. It is still unknown if benefits last after treatment ends, if progression speeds up, or how to taper treatments to prevent rebound. This is an important area for future research.\u003c\/p\u003e\n\u003ch3\u003eAre contact lenses safe for children with myopia?\u003c\/h3\u003e\n\u003cp\u003eContact lenses, including multifocal soft lenses and orthokeratology, increase the risk of eye infections. Orthokeratology lenses are worn overnight, adding hygiene concerns. The review noted that adverse events were not consistently reported. Proper hygiene, following replacement schedules, and reporting redness or pain promptly are essential.\u003c\/p\u003e\n\u003ch3\u003eMy child's doctor recommended atropine drops for myopia control. Should I get a second opinion on the treatment choice?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is reasonable when deciding among myopia control options because there are meaningful trade-offs. High-dose atropine slows progression most (about 0.90 D at one year) but causes glare and reading difficulty. Multifocal soft contact lenses and spectacles give smaller benefits with fewer side effects. Overall evidence certainty is only low to moderate, and side-effect reporting is inconsistent, so no single option is clearly superior. A second opinion can help confirm that the recommended dose or lens type fits your child's age, lifestyle, and tolerance. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003eThis patient-friendly article is based on the following peer-reviewed research:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Title:\u003c\/strong\u003e Interventions for myopia control in children: a living systematic review and network meta-analysis\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Lawrenson JG, Shah R, Huntjens B, Downie LE, Virgili G, Dhakal R, Verkicharla PK, Li D, Mavi S, Kernohan A, Li T, Walline JJ\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Cochrane Database of Systematic Reviews 2023, Issue 2. Art. No.: CD014758. DOI: 10.1002\/14651858.CD014758.pub2\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDisclaimer:\u003c\/strong\u003e This article is a translation of the original scientific paper for patient education purposes. It does not replace professional medical advice. Always consult a qualified eye care professional before making decisions about your child's treatment.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47471120941212,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/pt\/products\/myopia-control-in-children-a-complete-patients-guide-to-the-2023-cochrane-review","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}